TELEMEDICINE CONFERENCE by Akzhibek

Hi, my name is Musahanova Akzhibek 🫰🏻

Akzhibek041 — 2023-11-17 06:18:45 UTC

Akzhibek041 — 2023-11-17 06:20:01 UTC

Background

Akzhibek041 — 2023-11-17 06:22:30 UTC

People with inflammatory bowel disease (IBD) require intensive follow‐up with frequent consultations after diagnosis. IBD telehealth management includes consulting by phone, instant messenger, video, text message, or web‐based services. Telehealth can be beneficial for people with IBD, but may have its own set of challenges. It is important to systematically review the evidence on the types of remote or telehealth approaches that can be deployed in IBD. This is particularly relevant following the coronavirus disease 2019 (COVID‐19) pandemic, which led to increased self‐ and remote‐management.

Background (audio)

Akzhibek041 — 2023-11-17 06:32:54 UTC

Objectives

Akzhibek041 — 2023-11-17 06:34:01 UTC

To identify the communication technologies used to achieve remote healthcare for people with inflammatory bowel disease and to assess their effectiveness.

Search methods

Akzhibek041 — 2023-11-17 06:35:24 UTC

On 13 January 2022, we searched CENTRAL, Embase, MEDLINE, three other databases, and three trials registries with no limitations on language, date, document type, or publication status.

Selection criteria

Akzhibek041 — 2023-11-17 06:36:59 UTC

All published, unpublished, and ongoing randomised controlled trials (RCTs) that evaluated telehealth interventions targeted at people with IBD versus any other type of intervention or no intervention.We did not include studies based on digital patient information resources or education resources, unless they formed part of a wider package including an element of telehealth. We excluded studies where remote monitoring of blood or faecal tests was the only form of monitoring.

Data collection and analysis

Akzhibek041 — 2023-11-17 06:38:26 UTC

Two review authors independently extracted data from the included studies and assessed their risk of bias. We analysed studies on adult and paediatric populations separately. We expressed the effects of dichotomous outcomes as risk ratios (RRs) and the effects of continuous outcomes as mean differences (MDs) or standardised mean differences (SMDs), each with their 95% confidence intervals (CIs). We assessed the certainty of the evidence using GRADE methodology.

Main results

Akzhibek041 — 2023-11-17 06:40:43 UTC

We included 19 RCTs with a total of 3489 randomised participants, aged eight to 95 years. Three studies examined only people with ulcerative colitis (UC), two studies examined only people with Crohn's disease (CD), and the remaining studies examined a mix of IBD patients. Studies considered a range of disease activity states. The length of the interventions ranged from six months to two years. The telehealth interventions were web‐based and telephone‐based.

Conclusion (audio)

Akzhibek041 — 2023-11-17 06:46:06 UTC

Conclusion

Akzhibek041 — 2023-11-17 06:46:31 UTC

The evidence in this review suggests that web‐based disease monitoring is probably no different to standard care in adults when considering disease activity, occurrence of flare‐ups or relapse, and quality of life. There may be no difference in these outcomes in children, but the evidence is limited. Web‐based monitoring probably increases medication adherence slightly compared to usual care.

We are uncertain about the effects of web‐based monitoring versus usual care on our other secondary outcomes, and about the effects of the other telehealth interventions included in our review, because the evidence is limited.

Further studies comparing web‐based disease monitoring to standard care for the clinical outcomes reported in adults are unlikely to change our conclusions, unless they have longer follow‐up or investigate under‐reported outcomes or populations. Studies with a clearer definition of web‐based monitoring would enhance applicability, enable practical dissemination and replication, and enable alignment with areas identified as important by stakeholders and people affected by IBD.

041k group, General Medicine

Akzhibek041 — 2023-11-17 06:49:20 UTC

students:

Musahanova Akzhibek

Zharqyn Zhanzhalgas

Erbolqyzy Nurkamal

Orazymbekova Ayanat

Qozhahmet Akerke

Kenzhekhan Zhanmukhamed

Aitzhan Zhadyra

Kuatbek Nariman

Belturgan Nurkymbat

Assubayeva Aysana